Hester Biosciences

₹2,365As of Sun 8 Nov 2026, 12:00 UTC

NSE:HESTERBIOHealthcare

Country India

PE (Fwd) 32.40

TSR 10Y CAGR 12.47%

Div yield 0.47%

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.36

PE TTM 36.17

TSR TTM 48.17%

Mkt cap ₹19.49B

ROIC —

SE Grade™

Value

Quality

Moat

—

1Y Price

Reference

₹2,601

9.94%

(79.04%)

Price above Reference Value

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

3.341

Revenue₹B

—

2.466

2.782

3.112

3.125

3.341

3.567

7.88%

6.93

Revenue growth%

—

12.79

11.86

0.41

6.93

6.75

9.39

—

73.76

Gross margin%

—

72.50

70.35

67.95

70.29

73.76

73.70

70.35

20.74

Operating margin%

—

22.32

15.11

13.86

14.60

20.74

20.52

15.11

16.65

Net margin%

—

15.94

9.57

6.07

8.80

16.65

16.45

9.57

36.17

P/E ratio (avg)x

—

54.80

64.93

70.76

69.46

27.30

34.29

64.93

29.04

EV/EBITx

—

39.15

41.14

30.99

41.85

21.92

27.50

39.15

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

65.40

EPS₹

—

46.22

31.30

22.20

32.31

65.40

68.99

9.07%

—

102.41

EPS growth%

—

(32.28)

(29.06)

45.52

102.41

5.48

8.23

—

100

—

Bookvalue per sh₹

—

FCF per share₹

—

11.00

Dividend per sh₹

—

10.00

8.00

6.00

7.00

11.00

11.80

2.41%

—

0.47

Div yield (avg)%

—

0.39

0.38

0.31

0.62

0.50

0.39

16.82

Payout ratio%

—

21.63

25.56

27.02

21.66

16.82

17.10

21.66

8.507

Shares (diluted)M

—

8.507

◌8.507

—

Buyback yield%

—

◌—

—

D/E ratiox

—

20.12

Enterprise value₹B

—

21.55

17.29

13.37

19.09

15.19

20.12

(8.37%)

—

LT debt₹M

—

Peers (US$213.2M)

Cap (US$)

Windlas Biotech Limited

219.2M

31.91x

Indoco Remedies Limited

211.4M

62.81x

Venus Remedies Limited

206.5M

15.78x

Ginwa Enterprise…

212.7M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

9.345

8.162

Own earn%

—

Sh yield%

0.47

0.39

Owners

Insiders/Inst%

63.80

0.16

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

5/5

Revenue growth years

4/4

EPS growth years

2/4

Dividend streakyrs

Op margin range%

14–22

$1 testx

—

Incr. ROIC%

—

Hester Biosciences Limited manufactures and trades in veterinary vaccines and health products in India and internationally. It operates through two segments, Poultry Healthcare and Animal Healthcare.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹3.341B

7.88%

1.00×

Cost of revenue

₹876.6M

6.63%

0.95×

Operating expenses

₹1.772B

9.38%

1.06×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m